Blood product sterilization taken too far?

Certain processes used to sterilize blood products could potentially cause serious health issues in transfusion recipients, according to an international study published in the journal Platelets and led by Dr. Patrick Provost of Université Laval's Faculty of Medicine and the CHU de Québec Research Center. These processes purportedly alter the blood platelets to the extent of preventing them from carrying out their functions correctly and may be the cause of hemorrhages observed in patients having received treated blood.

The function of goes far beyond their role in and wound healing. They contain up to a third of the human genome in the form of ribonucleic acid (RNA), allowing them to synthesize over 1,000 proteins essential to the normal functioning of the human body.

The presence of this genetic material explains why platelets are affected by pathogen reduction treatments. "The processes that are used target the genetic material of pathogenic organisms," explains Patrick Provost. "They were developed more than 20 years ago, before we understood the importance of the contained in platelets."

Dr. Provost and his colleagues discovered that these treatments activate , triggering the release of RNA. "The platelets end up depleted of RNA so, once transfused, they're unable to do what they normally would," says the researcher.

The treatments are already on the market in some European countries, notably Switzerland, France, and Germany. Manufacturers are trying to get approval in other countries, including Canada and the United States. Professor Provost regrets the dearth of independent studies that have focused on the safety of the processes and hopes regulatory authorities such as Health Canada and the U.S. Food and Drug Administration will take these results into consideration. "In light of what we have demonstrated, the potentially harmful effects of these treatments should be carefully evaluated in the countries where they are not yet approved. It should also be re-evaluated in those countries where they are," concludes Provost.

add to favorites email to friend print save as pdf

Related Stories

Researchers find key to blood-clotting process

Jun 26, 2013

Researchers, including Professor Alastair Poole and Dr Matthew Harper from the University of Bristol's School of Physiology and Pharmacology, have uncovered a key process in understanding how blood clots ...

Insights into type 2B von Willebrand disease

Nov 25, 2013

In response to blood vessel damage, von Willebrand factor (vWF) binds to the exposed extra cellular matrix, recruits platelets to the site of injury, and activates platelets, which promotes thrombis formation. Patients with ...

Recommended for you

Educating on sickle cell risk

1 hour ago

Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.